John J. Rossi, Ph.D.

John Rossi, Ph.D., the Lidow Family Research Chair and professor and chair of the Department of Molecular and Cellular Biology, is widely regarded as a world leader in the development of RNA interference and in clinical research involving nucleic acids for the treatment of various diseases. Currently, he is focusing on enhancing the intracellular efficacy of ribozymes, small RNAs and siRNAi, and their application to gene therapy for HIV and cancer.

In 2019, he received the 2019 Outstanding Achievement Award presented by the American Society of Gene and Cell Therapy (ASGCT). The award is presented annually to the ASGCT member who has achieved pioneering research success and a lifetime of significant contributions to the field of gene and cell therapy. It is the society’s highest honor.

Dr. Rossi is the editor in chief of Molecular Therapy-Nucleic Acids and deputy editor of Molecular Therapy. He has authored more than 275 peer-reviewed papers and more than 70 book chapters. He is also founding president of Oligonucleotide Therapeutics Society. 
Dr. Rossi joined City of Hope in 1980 after receiving his Ph.D. in microbial and eukaryotic genetics at the University of Connecticut.

The Biology and Applications of Small RNAs

The Rossi Lab has as its primary focus studies on the functions and therapeutic applications of small RNAs. Within the past two decades there has been an explosion of new findings about roles that small RNAs play in biological processes. Ribozymes are RNA molecules with enzymatic activities. There are many different types of ribozymes in nature but our lab has focused upon the hammerhead motif which is found as part of the self-cleaving domain of small plant viruses. We have exploited these ribozymes for both basic studies of RNA catalysis and for therapeutic applications. Ribozymes developed in our research program have been developed to target HIV and these have been inserted into human blood progenitor cells via a retroviral vector as part of a gene therapy program for the treatment of HIV infection. To date 10 HIV positive patients have been treated with ribozymes developed in the lab. Efforts to improve catalytic efficiency and co-localization of ribozymes with their targets in mammalian cells are still an ongoing effort in the lab.

The recent discovery of RNA interference in which long double stranded RNAs or RNA hairpins are processed in smaller 21 to 23 base duplexes called small interfering RNAs and micro RNAs has revolutionized mammalian cell genetics. These small RNAs can be used to inhibit gene expression by targeting mRNAs with complementary sequences. The lab has been studying the mechanism of RNAi at the biochemical level, as well as exploiting this phenomenon for therapeutic applications in AIDS and cancer. One of our discoveries is that dsRNAs that are long enough to be processed by the RNAi machinery, but short enough not to activate the interferon pathway, called Dicer substrate siRNAs, have enhanced potency and duration of action relative to the 21 base long siRNAs used in most studies. One focus of the laboratory is to understand how linking processing with function enhances the activity of these siRNAs. Another area of research in the lab concerns the mechanisms by which small double stranded RNAs can trigger transcriptional gene silencing and activation by modulating the histone code. These small RNAs use components of the RNA interference machinery to target chromatin. A major effort in the lab is to elucidate the active components of this process and to apply transcriptional gene silencing in a therapeutic setting. Finally, the laboratory has been actively using an in vitro evolution process (SELEX) to evolve RNA aptamers for use as therapeutics, but also to serve as siRNA delivery vehicles. We have successfully evolved families of aptamers targeting the HIV envelope that neutralize HIV infectivity, yet can be internalized in HIV infected cells to deliver therapeutic siRNAs. Aptamers are also being selected against specific cellular receptors for use in cancer therapy.

• Reebye V, Saetrom P, Mintz PJ, Huang K-W, Swiderski P, Peng L, Liu C, Liu X, Lindkaer-Jensen S, Zacharoulis D, Kostomitsopoulos N, Kasahara N, Nicholls JP, Jiao LR, Pai M, Spalding DR, Mizandari M, Chikovain T, Emara MM, Haoudi A, Tomalia DA, Rossi JJ, Habib NA. (2014) A Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology  59(1): 216-227. PMCID: PMC4655108
• Voutila J, Reebye V, Roberts RC, Protopapa P, Andrikakou P, Balkey DC, Habib R, Huber H, Saetrom P, Rossi JJ, Habib N. (2017) Development and mechanism of small activating RNA targeting CEBPA, a novel therapeutic in clinical trials for liver cancer. Mol. Ther., 25(12): 2705-2714. PMCID: PMC5768526
• Zhou JH, Lazar D, Li H, Xia X, Satheesan S, Charlins P, O’Mealy D, Akkina R, Saayman S, Weinberg MS, Rossi JJ, Morris KV. (2018) Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics, 8(6): 1575-1590. PMCID: PMC5858168
• Reebye V, Huang K-W, Lin V, Jarvis S, Cutilas P, Dorman S, Ciriello S, Andrikakou P, Voutila J, Saetrom P, Mintz PJ, Reccia I, Rossi J.J, Huber H, Habib R, Kostomitsopoulos N, Balkey DC, Habib NA. (2018) Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drub candidate for liver cancer. Oncogene, 37(24): 3216-3228, PMCID: PMC6013054
• Zhou J, Li H, Xia X, Herrera A, Pollock N, Reebye V, Sodergren M, Dorman S, Littman B, Doogan D, Huang K-W, Habib R, Habib H, Rossi JJ. (2018) Anti-inflammatory activity of MTL-CEBPA, a small activating RNA drug, in LPS-stimulated monocytes and humanized mice. Mol. Ther., 27(5): 999-1016. PMCID: PMC6520465
• Huang KW, Reebye V, Czysz K, Ciriello S, Dorman S, Reccia I, Lai HS, Peng L, Kostomitsopoulos N, Nicolls J, Habib RS, Tomalia DA, Saetrom P, Wilkes E, Cutillas P, Rossi JJ, Habib NA. (2020) Liver Activation of Hepatocellular Nuclear Factor-4α by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile. Mol. Ther. Nucl. Acids. 19(6): 361-370. PMCID: PMC6938799
• Setten RL, Chomchan P, Epps EW, Burnett JD, Rossi JJ. (2021) CRED9: A differentially expressed elncRNA regulates expressing of transcription factor CEBPA. RNA J. RNA. 2021 Aug; 27(8): 891-906. doi: 10.1261/rna.078752.121  PMCID:  PMC8284328